Identification

Name
Fluocinolone Acetonide
Accession Number
DB00591  (APRD00977)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). It is also being investigated by Sivida and Alimera, under the brand name Medidur, as a sustained release intraocular implant for the treatment of diabetic macular edema.

Structure
Thumb
Synonyms
  • 6alpha-fluorotriamcinolone acetonide
  • 6alpha,9alpha-difluoro-16alpha-hydroxyprednisolone 16,17-acetonide
  • 6α-fluorotriamcinolone acetonide
  • 6α,9α-difluoro-16α-hydroxyprednisolone 16,17-acetonide
  • acétonide de fluocinolone
  • acetónido de fluocinolona
  • fluocinolon acetonid
  • fluocinolone 16,17-acetonide
  • fluocinoloni acetonidum
External IDs
NSC-92339
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CapexShampoo0.01 %TopicalGalderma2001-02-022014-07-15Canada
CapexKitGalderma1984-10-12Not applicableUs
Derma Smoothe/fs Liq 0.01%Liquid0.01 %TopicalHill Dermaceuticals, Inc.1991-12-31Not applicableCanada
Derma-Smoothe/FSOil.11 mg/mLTopicalHill Dermaceuticals, Inc.1988-02-032015-12-29Us
Derma-Smoothe/FSOil.11 mg/mLTopicalPhysicians Total Care, Inc.2009-09-03Not applicableUs
Derma-Smoothe/FSOil.11 mg/mLTopicalRoyal Pharmaceuticals1995-02-16Not applicableUs
Derma-Smoothe/FSOil.11 mg/mLTopicalHill Dermaceuticals, Inc.1995-02-162015-12-29Us
Derma-Smoothe/FSOil.11 mg/mLTopicalRoyal Pharmaceuticals1995-02-16Not applicableUs
DermOticOil.11 mg/mLAuricular (otic)Royal Pharmaceuticals2005-11-09Not applicableUs
DermOticOil.11 mg/mLAuricular (otic)Hill Dermaceuticals, Inc.2005-11-092015-12-29Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalAmneal Pharmaceuticals2015-09-22Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalTaro Pharmaceuticals U.S.A., Inc.2016-05-19Not applicableUs
Fluocinolone AcetonideOil.01 mg/100mLTopicalPerrigo New York Inc.2017-06-14Not applicableUs
Fluocinolone AcetonideCream.25 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone AcetonideOil.11 mg/20mLAuricular (otic)Av Kare, Inc.2013-12-18Not applicableUs
Fluocinolone AcetonideCream.25 mg/gTopicalGw Pharmaceuticals Ltd.2013-12-20Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalPhysicians Total Care, Inc.2012-04-26Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalAv Kare, Inc.2013-12-17Not applicableUs
Fluocinolone AcetonideOil.11 mg/mLAuricular (otic)Versa Pharm Incorporated2016-09-13Not applicableUs
Fluocinolone AcetonideSolution / drops.11 mg/mLAuricular (otic)Perrigo New York Inc.2017-10-04Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XilapakKitSolutech Pharmaceuticals Llc2017-11-01Not applicableUs
International/Other Brands
Coriphate / Cortiplastol / Dermalar (Teva) / Flucinar (Jelfa) / Flucort / Fluocet / Fluonid (Biolab) / Fluotrex / Fluovitif / Flupollon (Mayado Seiyaku) / Fluzon / Futocan (Shinlon) / Jellin (Grünenthal) / Locafluo (Recordati) / Localyn / Mecloderm (ICI) / Omniderm / Percutina / Prodermin / Radiocin / Sinalar / Synamol / Synandone / Synandrone / Synemol / Synotic / Synsac / Tefunote
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Neo-SynalarFluocinolone Acetonide (.25 mg/g) + Neomycin sulfate (3.5 mg/g)CreamTopicalMedimetriks Pharmaceuticals1963-06-11Not applicableUs
Neo-SynalarFluocinolone Acetonide + Neomycin sulfateKitMedimetriks Pharmaceuticals2014-07-15Not applicableUs
NoxipakFluocinolone Acetonide + UreaKitSolutech Pharmaceuticals Llc2017-11-01Not applicableUs
OtixalFluocinolone Acetonide (0.025 %) + Ciprofloxacin (0.3 %)SolutionAuricular (otic)Pediapharm Inc2017-05-08Not applicableCanada
OtovelFluocinolone Acetonide (62.5 ug/.25mL) + Ciprofloxacin (872.5 ug/.25mL) + Polysorbate 80 (6250 ug/.25mL)For solutionAuricular (otic)Arbor Pharmaceuticals2016-04-29Not applicableUs
Synalar Bi-otic SolutionFluocinolone Acetonide (0.25 mg) + Neomycin (3.5 mg) + Polymyxin B Sulfate (10000 unit)SolutionAuricular (otic)Medicis Pharmaceutical Corporation1986-12-311998-09-25Canada
Tri-lumaFluocinolone Acetonide (.1 mg/g) + Hydroquinone (40 mg/g) + Tretinoin (.5 mg/g)CreamTopicalGalderma2002-01-18Not applicableUs
Categories
UNII
0CD5FD6S2M
CAS number
67-73-2
Weight
Average: 452.4882
Monoisotopic: 452.201045102
Chemical Formula
C24H30F2O6
InChI Key
FEBLZLNTKCEFIT-VSXGLTOVSA-N
InChI
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Fluocinolone Acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Rapidly absorbed (15 minutes)

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Primarily hepatic, corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life

1.3-1.7 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluocinolone Acetonide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluocinolone Acetonide.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinolone Acetonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluocinolone Acetonide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluocinolone Acetonide.Approved, Withdrawn
AldesleukinFluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluocinolone Acetonide.Experimental
AloglutamolThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Fluocinolone Acetonide.Experimental
AluminiumThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinolone Acetonide.Approved
AmiodaroneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFluocinolone Acetonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluocinolone Acetonide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluocinolone Acetonide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinolone Acetonide.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocinolone Acetonide.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluocinolone Acetonide.Approved, Investigational
AprepitantThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinolone Acetonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinolone Acetonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinolone Acetonide.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fluocinolone Acetonide.Experimental
BendroflumethiazideFluocinolone Acetonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fluocinolone Acetonide.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluocinolone Acetonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluocinolone Acetonide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocinolone Acetonide.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fluocinolone Acetonide.Experimental
Bismuth SubcitrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinolone Acetonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluocinolone Acetonide.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluocinolone Acetonide.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fluocinolone Acetonide.Experimental
BumetanideFluocinolone Acetonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinolone Acetonide.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideFluocinolone Acetonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluocinolone Acetonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocinolone Acetonide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinolone Acetonide.Approved, Investigational
CeritinibFluocinolone Acetonide may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluocinolone Acetonide.Approved, Vet Approved
ChlorothiazideFluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneFluocinolone Acetonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocinolone Acetonide.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluocinolone Acetonide.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinolone Acetonide.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluocinolone Acetonide.Investigational
CyclopenthiazideFluocinolone Acetonide may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fluocinolone Acetonide.Investigational
DaidzeinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Daidzein.Experimental
DanazolFluocinolone Acetonide may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fluocinolone Acetonide.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluocinolone Acetonide.Approved, Vet Approved
DienestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fluocinolone Acetonide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinolone Acetonide.Approved
DihydrotestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluocinolone Acetonide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocinolone Acetonide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fluocinolone Acetonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluocinolone Acetonide.Approved
EquolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone.Approved
Etacrynic acidFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone Acetonide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fluocinolone Acetonide.Experimental
Ethinyl EstradiolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluocinolone Acetonide.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinolone Acetonide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluocinolone Acetonide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fluocinolone Acetonide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluocinolone Acetonide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinolone Acetonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluocinolone Acetonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluocinolone Acetonide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fluocinolone Acetonide.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluocinolone Acetonide.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluocinolone Acetonide.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluocinolone Acetonide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fluocinolone Acetonide.Experimental
FluoxymesteroneFluocinolone Acetonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluocinolone Acetonide.Approved, Investigational
FosaprepitantThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Fosphenytoin.Approved
FurosemideFluocinolone Acetonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with GI-5005.Investigational
GLPG-0492Fluocinolone Acetonide may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluocinolone Acetonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Fluocinolone Acetonide.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluocinolone Acetonide.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluocinolone Acetonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone Acetonide.Approved, Investigational
HydrochlorothiazideFluocinolone Acetonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFluocinolone Acetonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluocinolone Acetonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluocinolone Acetonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinolone Acetonide.Approved
IdelalisibThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fluocinolone Acetonide.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.Approved
IndapamideFluocinolone Acetonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluocinolone Acetonide.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinolone Acetonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluocinolone Acetonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluocinolone Acetonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluocinolone Acetonide.Withdrawn
ItraconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluocinolone Acetonide.Experimental
KetoconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinolone Acetonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinolone Acetonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluocinolone Acetonide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocinolone Acetonide.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fluocinolone Acetonide.Experimental
LopinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinolone Acetonide.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluocinolone Acetonide.Approved, Investigational
LumacaftorThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluocinolone Acetonide.Approved, Investigational
MagaldrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinolone Acetonide.Approved
Magnesium silicateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinolone Acetonide.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocinolone Acetonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinolone Acetonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinolone Acetonide.Approved
MesteroloneFluocinolone Acetonide may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinolone Acetonide.Investigational, Withdrawn
MethallenestrilThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinolone Acetonide.Approved, Vet Approved
MethyltestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Metoclopramide.Approved, Investigational
MetolazoneFluocinolone Acetonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Fluocinolone Acetonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinolone Acetonide.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fluocinolone Acetonide.Experimental
MoxestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinolone Acetonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinolone Acetonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinolone Acetonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinolone Acetonide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluocinolone Acetonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nalidixic Acid.Approved, Investigational
NandroloneFluocinolone Acetonide may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateFluocinolone Acetonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluocinolone Acetonide.Approved, Vet Approved
NefazodoneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluocinolone Acetonide.Approved
NevirapineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fluocinolone Acetonide.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinolone Acetonide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinolone Acetonide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluocinolone Acetonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinolone Acetonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinolone Acetonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluocinolone Acetonide.Vet Approved
OxandroloneFluocinolone Acetonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinolone Acetonide.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Oxolinic acid.Experimental
OxymetholoneFluocinolone Acetonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinolone Acetonide.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluocinolone Acetonide.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fluocinolone Acetonide.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluocinolone Acetonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinolone Acetonide.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluocinolone Acetonide.Approved, Investigational
PhenytoinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinolone Acetonide.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pipemidic acid.Experimental
PiretanideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinolone Acetonide.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinolone Acetonide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fluocinolone Acetonide.Experimental
Polyestradiol phosphateThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluocinolone Acetonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluocinolone Acetonide.Experimental, Investigational
PrimidoneThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fluocinolone Acetonide.Experimental
PromestrieneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluocinolone Acetonide.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fluocinolone Acetonide.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fluocinolone Acetonide.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluocinolone Acetonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluocinolone Acetonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide.Approved, Experimental, Investigational
RifabutinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluocinolone Acetonide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinolone Acetonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinolone Acetonide.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinolone Acetonide.Approved
SaquinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fluocinolone Acetonide.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocinolone Acetonide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluocinolone Acetonide.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluocinolone Acetonide.Investigational
St. John's WortThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololFluocinolone Acetonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinolone Acetonide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluocinolone Acetonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinolone Acetonide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fluocinolone Acetonide.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluocinolone Acetonide.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluocinolone Acetonide.Approved, Withdrawn
TelithromycinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fluocinolone Acetonide.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluocinolone Acetonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluocinolone Acetonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocinolone Acetonide.Approved
TestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateFluocinolone Acetonide may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinolone Acetonide.Approved
TiboloneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluocinolone Acetonide.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinolone Acetonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinolone Acetonide.Approved
TorasemideFluocinolone Acetonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinolone Acetonide.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluocinolone Acetonide.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluocinolone Acetonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocinolone Acetonide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinolone Acetonide.Approved
TromethamineThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinolone Acetonide.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Zoster vaccine.Approved
VoriconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFluocinolone Acetonide may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinolone Acetonide.Approved, Investigational
ZeranolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluocinolone Acetonide.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinolone Acetonide.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.

General References
  1. Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8. [PubMed:17923537]
  2. Brumm MV, Nguyen QD: Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64. [PubMed:17722513]
  3. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75. [PubMed:11006254]
External Links
Human Metabolome Database
HMDB14729
KEGG Drug
D01825
PubChem Compound
6215
PubChem Substance
46506244
ChemSpider
5980
ChEBI
31623
ChEMBL
CHEMBL989
Therapeutic Targets Database
DAP000813
PharmGKB
PA164754912
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluocinolone_acetonide
ATC Codes
S02BA08 — Fluocinolone acetonideS01CA10 — Fluocinolone acetonide and antiinfectivesS01BA15 — Fluocinolone acetonideS02CA05 — Fluocinolone acetonide and antiinfectivesD07BC02 — Fluocinolone acetonide and antisepticsD07CC02 — Fluocinolone acetonide and antibioticsC05AA10 — Fluocinolone acetonideD07AC04 — Fluocinolone acetonide
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (49.7 KB)
MSDS
Download (75.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentUveitis Affecting the Posterior Segment1
1CompletedTreatmentPsoriasis Vulgaris1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentBenign facial lentigines1
2TerminatedTreatmentAge-Related Macular Degeneration (ARMD)1
2TerminatedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)1
2, 3CompletedTreatmentDiabetic Macular Edema (DME)1
2, 3CompletedTreatmentNon-Infectious Uveitis1
2, 3CompletedTreatmentNoninfectious Posterior Uveitis1
2, 3TerminatedTreatmentNon-Infectious Uveitis1
3CompletedTreatmentDiabetic Macular Edema (DME)3
4Active Not RecruitingTreatmentDiabetic Macular Edema (DME)1
4CompletedTreatmentAllergies1
4CompletedTreatmentChronic Diabetic Macular Edema1
4CompletedTreatmentDiabetic Macular Edema (DME)1
4CompletedTreatmentMelasma1
4CompletedTreatmentUveitis1
4TerminatedTreatmentMelasma1
4Unknown StatusTreatmentNon-Infectious Uveitis / Ocular Behcet's Disease / Refractory Uveitis1
4WithdrawnTreatmentDiabetic Macular Edema (DME)1
Not AvailableCompletedPreventionSolar Lentigines1

Pharmacoeconomics

Manufacturers
  • Alpharma us pharmaceuticals division
  • E fougera div altana inc
  • G and w laboratories inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals usa inc
  • Usl pharma inc
  • Allergan herbert div allergan inc
  • Savage laboratories inc div altana inc
  • Medicis pharmaceutical corp
  • Bausch and lomb inc
  • Hill dermaceuticals inc
  • Galderma laboratories lp
  • Bausch and lomb pharmaceuticals inc
  • Morton grove pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
ShampooTopical0.01 %
LiquidTopical0.01 %
OilTopical.11 mg/mL
OilAuricular (otic).11 mg/mL
SolutionAuricular (otic)0.01 %
CreamTopical.1 mg/g
OilAuricular (otic).11 mg/20mL
OilTopical.01 mg/100mL
OilTopical.11 mg/118.28mL
Solution / dropsAuricular (otic).11 mg/mL
CreamTopical.01 %
CreamTopical.025 %
OintmentTopical.1 mg
OintmentTopical0.25 mg
ShampooTopical.01 %
ImplantIntravitreal.19 mg/1
CreamTopical
Kit
For solutionAuricular (otic)
ImplantIntravitreal.59 mg/1
ImplantIntravitreal0.59 mg
CreamTopical.25 mg/g
KitTopical
OintmentTopical.25 mg/g
SolutionTopical.1 mg/mL
SolutionAuricular (otic)
CreamTopical0.025 %
OintmentTopical0.025 %
OintmentTopical0.01 %
OintmentTopical.025 %
SolutionTopical0.01 %
Kit
CreamTopical0.01 %
Prices
Unit descriptionCostUnit
Retisert implant21900.0USD each
Synalar 0.01% Solution 60ml Bottle108.72USD bottle
Synalar 0.025% Cream 60 gm Tube103.1USD tube
Synalar 0.025% Ointment 60 gm Tube103.1USD tube
Fluocinolone Acetonide 0.01% Cream 15 gm Tube76.61USD tube
Fluocinolone Acetonide 0.01% Cream 60 gm Tube73.5USD tube
Fluocinolone Acetonide 0.025% Cream 15 gm Tube46.1USD tube
Fluocinolone Acetonide 0.025% Cream 60 gm Tube38.99USD tube
Fluocinolone Acetonide 0.025% Ointment 60 gm Tube38.99USD tube
Fluocinolone acetonide powder35.28USD g
Fluocinolone Acetonide 0.025% Ointment 15 gm Tube33.47USD tube
Fluocinolone Acetonide 0.01% Solution 60ml Bottle20.45USD bottle
Dermotic oil 0.01% ear drops1.75USD ml
Derma-smoothe-fs scalp oil0.35USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8247395No2002-10-222022-10-22Us
US8653053No2002-10-252022-10-25Us
US7939516No2005-05-042025-05-04Us
US7915243No2006-03-222026-03-22Us
US6217895No1999-03-222019-03-22Us
US6548078No1999-03-222019-03-22Us
US6375972No2000-04-262020-04-26Us
US8252307No1999-06-272019-06-27Us
US8871241No2007-08-122027-08-12Us
US8932610No2010-03-242030-03-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)266-268Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.
logP2.48HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0547 mg/mLALOGPS
logP2.47ALOGPS
logP1.6ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.35ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.41 m3·mol-1ChemAxon
Polarizability44.97 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.9683
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7912
P-glycoprotein inhibitor INon-inhibitor0.5674
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8304
CYP450 2C9 substrateNon-substrate0.8679
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9311
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8806
Ames testNon AMES toxic0.7682
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7033 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0il9-0496400000-d158ff1b8dbcf078b8ff
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-3981000000-e34007db14fcd7363a09

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Ketals / 1,3-dioxolanes / Alpha-hydroxy ketones / Secondary alcohols
show 9 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / 6-halo-steroid / Halo-steroid / Oxosteroid
show 27 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound, 11beta-hydroxy steroid, glucocorticoid, cyclic ketal, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:31623)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58. [PubMed:19744340]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phospholipase a2 activity
Specific Function
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
Gene Name
PLA2G4A
Uniprot ID
P47712
Uniprot Name
Cytosolic phospholipase A2
Molecular Weight
85238.2 Da
References
  1. Norris JF, Ilderton E, Yardley HJ, Summerly R, Forster S: Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. [PubMed:6743552]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18